Steven Gillis , Ph.D. is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. He is a director of Trubion Pharmaceuticals (TRBN), Allozyne, Variation Biotechnologies, Magen BioSciences, Surface Logix, PhaseRx, Accelerator, and Surface Logix. lifesciencesbc.ca
At Arch, Dr. Gillis focus is on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. slogix.th.net/about_us/board_of_directors.htm